Background: Innate immunity is generally impaired in chronic renal failure (CRF). Mannose-binding lectin (MBL) has an important role in first-line host defense against pathogens via the lectin pathway. We recently reported that functional MBL was significantly lower in CRF patients than in healthy subjects. In this study, we aimed to determine whether functional MBL would be improved following hemodialysis (HD) therapy. Methods: This study included 22 patients with end-stage renal disease (ESRD) on maintenance HD. Functional MBL was measured every 6 months for 1 year after HD using an enzyme-linked immunosorbent assay. Results: Median serum functional MBL levels of ESRD patients were significantly higher after 6 and 12 months than at the start of HD therapy (p < 0.05 and p < 0.01, respectively). Furthermore, median functional MBL levels at 12 months were significantly higher than those at 6 months (p < 0.05). Conclusions: We found significant increases in serum functional MBL levels in patients on HD. Our results indicated that HD tailored to remove uremic toxins could improve functional MBL levels in these patients.

Keywords:
Chronic renal failure, Diabetes, ELISA, End-stage renal disease, Hemodialysis, Infection, Innate immunity, Mannose-binding lectin
1.
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008;3:1526–1533.
2.
Girndt M, Sester M, Sester U, Kaul H, Kohler H: Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001;78:S206–S211.
3.
Iida T, Umezawa K, Tanaka K, Koga Y, Nakazawa H, Satoh T: Polymorphonuclear cells in chronic hemodialysis patients have intact phagocytotic and impaired bactericidal activities. Nephron 1997;75:41–47.
4.
Vanholder R, Ringoir S: Polymorphonuclear cell function and infection in dialysis. Kidney Int Suppl 1992;38:S91–S95.
5.
Gerez L, Madar L, Shkolnik T, Kristal B, Arad G, Reshef A, Steinberger A, Ketzinel M, Sayar D, Shasha S, et al: Regulation of interleukin-2 and interferon-gamma gene expression in renal failure. Kidney Int 1991;40:266–272.
6.
Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 1980;93:597–613.
7.
Sarnak MJ, Jaber BL: Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000;58:1758–1764.
8.
Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Marubayashi S, Morita O, Yamagata K, Wakai K, Watanabe Y, Iseki K, Tsubakihara Y: Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 2010;14:505–540.
9.
Ando M, Shibuya A, Tsuchiya K, Akiba T, Nitta K: Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients. Kidney Int 2006;70:358–362.
10.
Lim WH, Kireta S, Leedham E, Russ GR, Coates PT: Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 2007;72:1138–1148.
11.
Kawasaki N, Kawasaki T, Yamashina I: Isolation and characterization of a mannan-binding protein from human serum. J Biochem 1983;94:937–947.
12.
Wild J, Robinson D, Winchester B: Isolation of mannose-binding proteins from human and rat liver. Biochem J 1983;210:167–174.
13.
Summerfield JA, Taylor ME: Mannose-binding proteins in human serum: identification of mannose-specific immunoglobulins and a calcium-dependent lectin, of broader carbohydrate specificity, secreted by hepatocytes. Biochim Biophys Acta 1986;883:197–206.
14.
Matsushita M: The lectin pathway of the complement system. Microbiol Immunol 1996;40:887–893.
15.
Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ, Turner MW: Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000;68:688–693.
16.
Ezekowitz RA, Day LE, Herman GA: A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med 1988;167:1034–1046.
17.
Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC: The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 1992;90:31–35.
18.
Satomura A, Fujita T, Fuke Y, Yanai M, Kumasaka K, Takayama E, Hamada H, Maruyama T, Nakayama T: Relationship between oligomer and functional serum mannose-binding lectin in chronic renal failure. Eur J Clin Invest 2010;40:865–873.
19.
Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR: Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006;17:1724–1734.
20.
Xing GQ, Chen M, Liu G, Zheng X, E J, Zhao MH: Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. J Clin Immunol 2010;30:144–156.
21.
Ibernon M, Moreso F, Moreno JM, Bestard O, Cruzado JM, Grinyo JM, Ricart W, Fernandez-Real JM, Seron D: Low serum mannose-binding lectin as a risk factor for new onset diabetes mellitus after renal transplantation. Transplantation 2009;88:272–278.
22.
Simera I, Moher D, Hoey J, Schulz KF, Altman DG: A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35–53.
23.
Masuda M, Komiyama Y, Murakami T, Murata K: Decrease of polymorphonuclear leukocyte membrane fluidity in uremic patients on hemodialysis. Nephron 1990;54:36–41.
24.
Vanholder R, De Smet R, Jacobs V, Van Landschoot N, Waterloos MA, Vogeleere P, Ringoir S: Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 1994;9:1271–1278.
25.
Jorstad S, Viken KE: Inhibitory effects of plasma from uraemic patients on human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand C 1977;85:169–177.
26.
Jorstad S, Kvernes S: Uraemic toxins of high molecular weight inhibiting human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand C 1978;86C:221–226.
27.
Porter CJ, Burden RP, Morgan AG, Daniels I, Fletcher J: Impaired polymorphonuclear neutrophil function in end-stage renal failure and its correction by continuous ambulatory peritoneal dialysis. Nephron 1995;71:133–137.
28.
Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, Turner MW: Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995;345:886–889.
29.
Manuel O, Pascual M, Trendelenburg M, Meylan PR: Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007;83:359–362.
30.
Berger SP, Roos A, Mallat MJ, Schaapherder AF, Doxiadis II, van Kooten C, Dekker FW, Daha MR, de Fijter JW: Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2007;18:2416–2422.
31.
Satomura A, Endo M, Ohi H, Sudo S, Ohsawa I, Fujita T, Matsushita M: Significant elevations in serum mannose-binding lectin levels in patients with chronic renal failure. Nephron 2002;92:702–704.
32.
Terai I, Kobayashi K, Fujita T, Hagiwara K: Human serum mannose binding protein (MBP): development of an enzyme-linked immunosorbent assay (ELISA) and determination of levels in serum from 1085 normal Japanese and in some body fluids. Biochem Med Metab Biol 1993;50:111–119.
33.
Satomura A, Fujita T, Matsumoto K: Mannose-binding lectin level and polymorphism in patients on long-term peritoneal dialysis – level of serum mannose binding lectin with end-stage renal disease. Nephrol Dial Transplant 2006;21:1729–1730, author reply 1730–1731.
34.
Satomura A, Endo M, Fujita T, Ohi H, Ohsawa I, Fuke Y, Matsumoto K, Sudo S, Matsushita M: Serum mannose-binding lectin levels in maintenance hemodialysis patients: impact on all-cause mortality. Nephron Clin Pract 2006;102:c93–c99.
35.
Akbari R, Mireskandari M, Alizadeh-Navaei R, Ghods A: Measurement of serum levels of mannose-binding lectin in hemodialysis patients: a comparison with healthy individuals. Iran J Kidney Dis 2011;5:255–259.
36.
Tsutsumi A, Sasaki K, Wakamiya N, Ichikawa K, Atsumi T, Ohtani K, Suzuki Y, Koike T, Sumida T: Mannose-binding lectin gene: polymorphisms in Japanese patients with systemic lupus erythematosus, rheumatoid arthritis and Sjögren’s syndrome. Genes Immun 2001;2:99–104.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.